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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is an
autoinflammatory syndrome caused by heterozygous
mutations of CIAS1/NLRP3 gene. Affected patients may
present with three different phenotypes: familial cold auto-
inflammatory syndrome (FCAS), Muckle-Wells syndrome
and CINCA syndrome. Common symptoms include
sporadic or cold-induced non pruritic urticarial rash and
fever. Severe cases suffer from deafness, meningitis, articu-
lar contracture and secondary amyloidosis.
Case Report
We describe a 13-year-old female who complained, start-
ing at 12 years of age, of recurrent episodes of high fever,
pericarditis, arthralgia, arthritis of the knees, abdominal
pain. These episodes were associated with marked increase
in inflammatory markers and in serum amyloid level
(5 episodes in the first 5 months of disease). Symptoms
were poorly responsive to NSAIDs and colchicine but
responded to steroid therapy. Molecular analysis of the
MEFV, TNFR and MVK genes did not show any patho-
genic mutations. In the subsequent months she developed
recurrent (up to daily) episodes of chest pain, skin rash
and swelling of the subcutaneous tissue of limbs, trunk,
joints and lips, in the absence of fever, with spontaneous
resolution.
Molecular analysis of the CIAS1 gene revealed the pre-
sence of a c.1105C>A mutation in the heterozygous state,
that predicts a L369M amino acid substitution. To the
best of our knowledge this variant has never been
reported. One hundred chromosomes were examined and
the variant was not found. In order to verify the potential
pathogenic effects of the L369M amino acid substitution,
daily therapy with anakinra (2 mg/kg/day) was started
with rapid disappearance of clinical symptoms and nor-
malization of CRP levels in 24 hours. Since the pathogenic
significance of the mutation observed is not known,
prediction of the effect of this mutation on the protein
function has been attempted, in silico, by subjecting the
p.L369M substitution to the Variant Effect Predictor tool.
The mutation was predicted to significantly affect protein
structure (scoring as “dangerous” and “deleterious”).
Discussion
The fast response to IL-1 inhibition suggests that the
disease of this patient is driven by IL-1 and support the
conclusion that this novel mutation is pathogenic and may
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